Effect of dasatinib treatment on tumor antigen-specific T-cell response. (A) Representative dot plots for P1A tetramer staining in the periphery blood of vehicle- or dasatinib-treated mice. (B) Percentages of P1A tetramer⁺ T cells in total CD8⁺ T cells (*P = .0235). (C) Representative dot plots for intracellular IFN-γ staining. (D) Percentages of IFN-γ⁺ T cells in total CD8⁺ T cells (P1A: *P = .0449, P1E: *P = .0498). (E) IFN-γ secretion by peripheral blood T cells in response to P1A or P1E peptides detected by ELISA (P1A: *P = .0428, P1E: **P = .0017). (F) P1A tetramer staining of the CD4⁺ T-cell depletion experiment.